Tranexamic acid in total hip arthroplasty

INTERVENTION: A sample was divided into two groups. The control group underwent total hip prosthesis of Non cemented as the usual protocol Used at the National Institute of Trauma ‐ Orthopedics. The group case , was subjected to the same procedure , using the same protocol , the One difference was a aplicacação of medication acid tranexamic intravenous , 15mg per kg weight, single dose , 15 minutes before the start of Surgical incision. Each group was Compound by 128 patients. Samples were not paired. E07.695.400.400 H02.403.810.494 CONDITION: Hip artritis / Total hip replacement ; M16 ; Z44.9 M00‐M99 PRIMARY OUTCOME: Blood loss was 1,163 mL in the control group and 652.9 mL in the treated group (p <0.0001). Reduction in the need for postoperative blood transfusion, verified by the volume of red blood cells used in the postoperative period. Reduction of bleeding during the early post operative, verified by measuring the bleeding by the formula that uses the variation of hematocrit pre and post operative; The need for postoperative blood transfusion was lower in the treated patients (14.1% vs 32%, p = 0.001). In addition, a lower volume of packed red blood cells was used in the treated group (300 mL) than in the control group (600 mL) (p <0.0001). SECONDARY OUTCOME: Although the median hospitalization time was the same in both groups, in the control group the variation in hospitalization time was 3 to 5 days, while in the treated group it was 3 to 7 days (p = 0.0001 ). In the treated group, there was a reduction of 12.9% in the Hb value and 13.1% in the postoperative Ht, whereas in the control group there was a 23% decrease in the Hb value and 22.7% in the Ht value Postoperative (p <0.0001). Reduction in hospital stay time in the treated group. Reduction of the fall in the value of postoperative Hb and Ht. INCLUSION CRITERIA: Primary total hip replacement